Geoffrey Gottlieb is an Infectious Disease physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1959 NE Pacific St
Seattle, WA 981956166
Telephone
206-598-7600Registry record last updated 18 Dec 2018.
Clinical trials
- RESIST-2: 2nd-line ART for HIV-2 Infection
Sponsor: University of Washington
- Demonstration Project of PrEP Among Female Sex Workers in Dakar, Senegal
Sponsor: Réseau Africain de Recherche sur le SIDA
- An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Sponsor: University of Washington
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
84.3%Azole Antifungal24.1%Fluconazole100%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor16.9%Dovato100%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
15.7%Proton pump inhibitor15.7%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2001–2025 per NIH RePORTER. The latest:
- Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
University of Washington
FY2025$594,778R01AI120765 - Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
University of Washington
FY2025$185,410R01AI120765 - Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
University of Washington
FY2024$725,239R01AI120765
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”